Aktie A40E1B JAGUAR HEALTH, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Jaguar Health, Inc.

Aktien

A40E1B

US47010C8055

JAGX

Realtime-Estimate Cboe BZX
Andere Börsenplätze
 19:35:08 01.07.2024 		% 5 Tage % 1. Jan.
3,555 USD -0,70 % Intraday Chart für Jaguar Health, Inc. -6,07 % -60,81 %
30.05. Top Premarket Gainers MT
29.05. Jaguar Health erweitert Auslizenzierungsvereinbarung mit Magdalena Biosciences MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
Jaguar Health : Corporate Presentation – June 21, 2024
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Jaguar Health : Private Placement Form 8 K
Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV
Top Premarket Gainers
Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences
Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional Diarrhea
Jaguar Health, Inc. Executes Out- License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Jaguar Health, Inc. Announces Results of Third-Party, Investigator-Initiated Study of Crofelemer
Jaguar Health Announces Reverse Stock Split
Jaguar Health Plans 1-for-60 Reverse Split Next Week
Jaguar Health : Corporate Presentation – May 15, 2024
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials and Corporate Updates
Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment
Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion about Microvillus Inclusion Disease
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society Congress in Support of Company's Expanding Focus on Cancer Supportive Care
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A40E1B Aktie
  4. Nachrichten Jaguar Health, Inc.
  5. Andere Sprachen